Prespecified analysis of the STEP-HFpEF trial of semaglutide in people with obesity and heart failure with preserved ejection fraction showed a positive link between weight-loss amounts and outcomes.
In STEP-HFpEF, a prospective, randomized study of adults with HFpEF and obesity, weekly semaglutide weight-loss injections for 1 year led to substantial improvements in physical function and symptoms.
Sotagliflozin, a novel inhibitor of both SGLT 1 and 2, enters the US market with indications for preventing CV events, especially heart failure hospitalization and acute exacerbations.
Empagliflozin showed symptomatic benefits in patients hospitalized for acute heart failure after 2 weeks in a secondary analysis from the EMPULSE trial.